Varenicline
DrugOther names: Chantix, Champix
NCT Number: NCT00463918
This study will investigate the multiple dose pharmacokinetics, safety, and tolerability of two dose strengths of varenicline in adolescents aged 12 to 16 years who regularly smoke at least three cigarettes per day.
Looking for future studies?
Notify Me12 year–16 year
All sexes
Interventional
Phase 1
Pfizer Investigational Site, Slough, Berkshire, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Chantix, Champix
Looking for future studies?
Notify MePfizer
Industry
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-Dose Pharmacokinetics, Safety and Tolerability of Varenicline in Healthy Adolescent Smokers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05004662
Behavior, Health Behavior
Tampa, Florida, United States
View Trial DetailsNCT06746025
Behavior, Behavior, Addictive
Naples, Florida, United States
View Trial DetailsNCT03714971
Behavior, Health Behavior
Izmir, Turkey (Türkiye)
View Trial DetailsNCT06909357
Behavior, Health Behavior
Coral Gables, Florida, United States
View Trial Details